1 Study Coverage
1.1 Becker Muscular Dystrophy Drug Product Introduction
1.2 Market Segments
1.3 Key Becker Muscular Dystrophy Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Becker Muscular Dystrophy Drug Market Size Growth Rate by Type
1.4.2 Givinostat
1.4.3 Ataluren
1.4.4 Epicatechin
1.4.5 ARM-210
1.4.6 Others
1.5 Market by Application
1.5.1 Global Becker Muscular Dystrophy Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Becker Muscular Dystrophy Drug Market Size, Estimates and Forecasts
2.1.1 Global Becker Muscular Dystrophy Drug Revenue 2015-2026
2.1.2 Global Becker Muscular Dystrophy Drug Sales 2015-2026
2.2 Global Becker Muscular Dystrophy Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Becker Muscular Dystrophy Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Becker Muscular Dystrophy Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Becker Muscular Dystrophy Drug Competitor Landscape by Players
3.1 Becker Muscular Dystrophy Drug Sales by Manufacturers
3.1.1 Becker Muscular Dystrophy Drug Sales by Manufacturers (2015-2020)
3.1.2 Becker Muscular Dystrophy Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Becker Muscular Dystrophy Drug Revenue by Manufacturers
3.2.1 Becker Muscular Dystrophy Drug Revenue by Manufacturers (2015-2020)
3.2.2 Becker Muscular Dystrophy Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Becker Muscular Dystrophy Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Becker Muscular Dystrophy Drug Revenue in 2019
3.2.5 Global Becker Muscular Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Becker Muscular Dystrophy Drug Price by Manufacturers
3.4 Becker Muscular Dystrophy Drug Manufacturing Base Distribution, Product Types
3.4.1 Becker Muscular Dystrophy Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Becker Muscular Dystrophy Drug Product Type
3.4.3 Date of International Manufacturers Enter into Becker Muscular Dystrophy Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Becker Muscular Dystrophy Drug Market Size by Type (2015-2020)
4.1.1 Global Becker Muscular Dystrophy Drug Sales by Type (2015-2020)
4.1.2 Global Becker Muscular Dystrophy Drug Revenue by Type (2015-2020)
4.1.3 Becker Muscular Dystrophy Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Becker Muscular Dystrophy Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Becker Muscular Dystrophy Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Becker Muscular Dystrophy Drug Revenue Forecast by Type (2021-2026)
4.2.3 Becker Muscular Dystrophy Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Becker Muscular Dystrophy Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Becker Muscular Dystrophy Drug Market Size by Application (2015-2020)
5.1.1 Global Becker Muscular Dystrophy Drug Sales by Application (2015-2020)
5.1.2 Global Becker Muscular Dystrophy Drug Revenue by Application (2015-2020)
5.1.3 Becker Muscular Dystrophy Drug Price by Application (2015-2020)
5.2 Becker Muscular Dystrophy Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Becker Muscular Dystrophy Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Becker Muscular Dystrophy Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Becker Muscular Dystrophy Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Becker Muscular Dystrophy Drug by Country
6.1.1 North America Becker Muscular Dystrophy Drug Sales by Country
6.1.2 North America Becker Muscular Dystrophy Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Becker Muscular Dystrophy Drug Market Facts & Figures by Type
6.3 North America Becker Muscular Dystrophy Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Becker Muscular Dystrophy Drug by Country
7.1.1 Europe Becker Muscular Dystrophy Drug Sales by Country
7.1.2 Europe Becker Muscular Dystrophy Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Becker Muscular Dystrophy Drug Market Facts & Figures by Type
7.3 Europe Becker Muscular Dystrophy Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Becker Muscular Dystrophy Drug by Region
8.1.1 Asia Pacific Becker Muscular Dystrophy Drug Sales by Region
8.1.2 Asia Pacific Becker Muscular Dystrophy Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Becker Muscular Dystrophy Drug Market Facts & Figures by Type
8.3 Asia Pacific Becker Muscular Dystrophy Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Becker Muscular Dystrophy Drug by Country
9.1.1 Latin America Becker Muscular Dystrophy Drug Sales by Country
9.1.2 Latin America Becker Muscular Dystrophy Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Becker Muscular Dystrophy Drug Market Facts & Figures by Type
9.3 Central & South America Becker Muscular Dystrophy Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Becker Muscular Dystrophy Drug by Country
10.1.1 Middle East and Africa Becker Muscular Dystrophy Drug Sales by Country
10.1.2 Middle East and Africa Becker Muscular Dystrophy Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Becker Muscular Dystrophy Drug Market Facts & Figures by Type
10.3 Middle East and Africa Becker Muscular Dystrophy Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Italfarmaco SpA
11.1.1 Italfarmaco SpA Corporation Information
11.1.2 Italfarmaco SpA Description and Business Overview
11.1.3 Italfarmaco SpA Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Italfarmaco SpA Becker Muscular Dystrophy Drug Products Offered
11.1.5 Italfarmaco SpA Related Developments
11.2 Milo Biotechnology LLC
11.2.1 Milo Biotechnology LLC Corporation Information
11.2.2 Milo Biotechnology LLC Description and Business Overview
11.2.3 Milo Biotechnology LLC Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Milo Biotechnology LLC Becker Muscular Dystrophy Drug Products Offered
11.2.5 Milo Biotechnology LLC Related Developments
11.3 PTC Therapeutics Inc
11.3.1 PTC Therapeutics Inc Corporation Information
11.3.2 PTC Therapeutics Inc Description and Business Overview
11.3.3 PTC Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 PTC Therapeutics Inc Becker Muscular Dystrophy Drug Products Offered
11.3.5 PTC Therapeutics Inc Related Developments
11.4 ReveraGen BioPharma Inc
11.4.1 ReveraGen BioPharma Inc Corporation Information
11.4.2 ReveraGen BioPharma Inc Description and Business Overview
11.4.3 ReveraGen BioPharma Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 ReveraGen BioPharma Inc Becker Muscular Dystrophy Drug Products Offered
11.4.5 ReveraGen BioPharma Inc Related Developments
11.5 Sarepta Therapeutics Inc
11.5.1 Sarepta Therapeutics Inc Corporation Information
11.5.2 Sarepta Therapeutics Inc Description and Business Overview
11.5.3 Sarepta Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Sarepta Therapeutics Inc Becker Muscular Dystrophy Drug Products Offered
11.5.5 Sarepta Therapeutics Inc Related Developments
11.1 Italfarmaco SpA
11.1.1 Italfarmaco SpA Corporation Information
11.1.2 Italfarmaco SpA Description and Business Overview
11.1.3 Italfarmaco SpA Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Italfarmaco SpA Becker Muscular Dystrophy Drug Products Offered
11.1.5 Italfarmaco SpA Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Becker Muscular Dystrophy Drug Market Estimates and Projections by Region
12.1.1 Global Becker Muscular Dystrophy Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Becker Muscular Dystrophy Drug Revenue Forecast by Regions 2021-2026
12.2 North America Becker Muscular Dystrophy Drug Market Size Forecast (2021-2026)
12.2.1 North America: Becker Muscular Dystrophy Drug Sales Forecast (2021-2026)
12.2.2 North America: Becker Muscular Dystrophy Drug Revenue Forecast (2021-2026)
12.2.3 North America: Becker Muscular Dystrophy Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Becker Muscular Dystrophy Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Becker Muscular Dystrophy Drug Sales Forecast (2021-2026)
12.3.2 Europe: Becker Muscular Dystrophy Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Becker Muscular Dystrophy Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Becker Muscular Dystrophy Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Becker Muscular Dystrophy Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Becker Muscular Dystrophy Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Becker Muscular Dystrophy Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Becker Muscular Dystrophy Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Becker Muscular Dystrophy Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Becker Muscular Dystrophy Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Becker Muscular Dystrophy Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Becker Muscular Dystrophy Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Becker Muscular Dystrophy Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Becker Muscular Dystrophy Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Becker Muscular Dystrophy Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Becker Muscular Dystrophy Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Becker Muscular Dystrophy Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
【掲載企業】
Italfarmaco SpA、Milo Biotechnology LLC、PTC Therapeutics Inc、ReveraGen BioPharma Inc、Sarepta Therapeutics Inc
【免責事項】
https://www.globalresearch.jp/disclaimer